# Shinsei Capital Partners

Shinsei Capital Partners is a Private Equity based in Tokyo, Japan.

## Overview

- **Organization type:** Private Equity
- **Headquarters:** Tokyo, Japan
- **Region:** Asia
- **Address:** 5-13-1 Toranomon, Minato-ku, Tokyo, Japan
- **Founded:** 2019
- **Assets under management:** <$50M USD (Altss estimate)
- **Website:** www.new-lifescience.com
- **LinkedIn:** https://www.linkedin.com/company/shinsei-capital-partners

## Regulatory record

- **Reports private funds:** No

## About

Shinsei Capital Partners financially supports research from universities, research institutions, and pharmaceutical companies to help commercialize innovative medicines. The firm operates the New Life Science Fund No. 1 and invests in drug-discovery ventures across company-creation, seed, early, middle, and later stages, drawing on finance and pharmaceutical-development experience.

## Sectors

- Biotech
- Healthcare Services

## People

- Manabu Nakamura — Managing Partner / CEO
- Ryo Fujinami — Partner

## Questions

### Who runs investment decisions at Shinsei Capital Partners?

Managing Partner Manabu Nakamura leads investment decisions. He built his career at Japan Long-Term Credit Bank, NED venture capital, and Shinsei Corporate Investment, where he spent over a decade before spinning out. Partner Ryo Fujinami, a former Abbott Japan diagnostics R&D scientist, provides in-house scientific underwriting capacity.

### How is Shinsei Capital Partners related to SBI Shinsei Bank?

The firm's sole fund, New Life Science I Investment Limited Partnership, has Shinsei Capital Partners as its general partner. SBI Shinsei Bank executive Takahisa Komoda serves as a director of the GP, linking the fund to the bank's broader private equity and corporate-investment activity. The bank is not listed as a limited partner in public disclosures.

### Does Shinsei Capital Partners invest outside Japan?

All disclosed activity is domestic. The firm's stated mission is to fund Japanese academic research and help translate it into medicines serving patient needs. No non-Japanese portfolio companies or overseas offices appear in any public source.

## Related profiles

- [Shinsei Business Succession](https://altss.com/profile/shinsei-business-succession)
- [Shinsei Impact Investment](https://altss.com/profile/shinsei-impact-investment)

---

Last updated: 2026-08-11T15:08:04.536Z

Canonical page: https://altss.com/profile/shinsei-capital-partners

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology